Sirlift, 100 mg 28 pcs.

Sertraline is a potent and selective serotonin reuptake inhibitor (5NT). At clinical doses, Sertraline blocks serotonin uptake in human platelets.
Sertraline has no affinity for muscarinic (cholinergic), serotonin, dopamine, histamine, benzodiazepine and adrenergic receptors.

Sertraline does not cause drug dependence, does not have m-cholinoblocking and cardiotoxic effects. It does not increase the activity of the sympathetic nervous system.

In contrast to tricyclic antidepressants it does not increase body weight.

Pharmacokinetics

Sertraline is slowly adsorbed from the gastrointestinal tract. Food intake has no significant effect on the bioavailability of the drug. Sertraline undergoes active first-pass metabolism through the liver. The main metabolite, N-desmethylsertraline, is significantly inferior in activity to sertraline and has almost no antidepressant effect. Equilibrium concentrations are reached after about a week of treatment (once daily), with double cumulation of the drug. Binding to plasma proteins is 98%.

The average half-life of Sertraline is 22-36 hours. Sertraline and N-desmethylsertraline are actively biotransformed; the resulting metabolites are excreted in equal amounts in the feces and urine. Only 0.2% of sertraline is excreted unchanged by the kidneys. Pharmacokinetics of the drug in elderly and young patients is not significantly different.

Sertraline penetrates into the breast milk.

There is no data on its ability to pass through the blood-placental barrier.

Certralin is not dialyzed.

Indications

Treatment and prevention of depressive states of varying severity (from mild to severe), including those accompanied by feelings of anxiety and suicidal attempts;
Neurotic, somatoform depression;
Post-traumatic stress disorder (PTSD);
Obsessive-compulsive disorders (OCD);
Treatment of panic disorders, accompanied or not accompanied by agoraphobia and other phobias;
Treatment of anorexia nervosa, bulimia and chronic pain syndromes.

Pharmacological effect

Sertraline is a potent and selective serotonin reuptake inhibitor (5HT). At clinical doses, sertraline blocks the uptake of serotonin into human platelets.
Sertraline has no affinity for muscarinic (cholinergic), serotonin, dopamine, histamine, benzodiazepine and adrenergic receptors.

Sertraline does not cause drug dependence and does not have m-anticholinergic or cardiotoxic effects. Does not enhance the activity of the sympathetic nervous system.

Unlike tricyclic antidepressants, it does not increase body weight.

Pharmacokinetics

Sertraline is slowly absorbed from the gastrointestinal tract. Food intake does not have a significant effect on the bioavailability of the drug. Sertraline undergoes extensive first-pass metabolism through the liver. The main metabolite, N-desmethylsertraline, is significantly inferior in activity to sertraline and has virtually no antidepressant effect. Equilibrium concentrations are achieved after approximately a week of treatment (once a day), and a twofold cumulation of the drug is observed. Plasma protein binding is 98%.

The average half-life of sertraline is 22-36 hours. Sertraline and N-desmethylsertraline are actively biotransformed, the resulting metabolites are excreted in feces and urine in equal quantities. Only 0.2% of sertraline is secreted unchanged by the kidneys. The pharmacokinetics of the drug in elderly and young patients does not differ significantly.

Sertraline passes into breast milk.

There is no data on its ability to pass through the hematoplacental barrier.

Sertraline is not dialysable.

Special instructions

Sirlift should not be prescribed in conjunction with an MAOI, or within 14 days after stopping treatment with an MAOI. After discontinuation of Serlift, no MAOIs are prescribed for 14 days. During treatment with Surlift, care must be taken when driving vehicles and potentially dangerous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Sertraline

Composition

1 film-coated tablet contains:

active ingredient:

sertraline hydrochloride 100 mg.

Pregnancy

Adequate controlled trials of sertraline in pregnant and lactating women have not been conducted; Surlift may be prescribed when the expected benefit to the mother outweighs the possible risk to the fetus and child.

Contraindications

Hypersensitivity to the active substance or other ingredients included in the drug Serlift.
Combined use of sertraline and MAO inhibitors
Concomitant use of sertraline with tryptophan or phenylfluramine
Combined use with pimozide
Epilepsy during exacerbation
Children under 6 years old
Pregnancy and lactation

Side Effects

From the nervous system and sensory organs: drowsiness, dizziness, headache, insomnia, confusion, amnesia, ataxia, incoordination, hyper- and paresthesia, hyperkinesis, hypo- and dyskinesia, extrapyramidal disorders, convulsions, mydriasis, nystagmus, ptosis, hyporeflexia, aggressiveness, anxiety, psychosis, amnesia, apathy, depersonalization, emotional lability, euphoria, hallucinations, paranoid reactions, somnambulism.

From the cardiovascular system and blood (hematopoiesis, hemostasis): arterial hypertension or arterial hypotension, palpitations, chest pain, anemia; rarely – tachycardia, collaptoid states.

From the gastrointestinal tract: dry mouth, decreased appetite up to anorexia (rarely – increased appetite, possibly as a result of eliminating depression), dyspeptic disorders (flatulence, nausea, vomiting, diarrhea or unstable stool, constipation), stomach cramps, abdominal pain, pancreatitis, changes in liver tests, hepatitis, jaundice or liver failure, dysphagia, irritation of the gastrointestinal mucosa, glossitis, gum hypertrophy, ulcerative stomatitis.

From the respiratory system: a feeling of chest compression.

From the genitourinary system: delayed ejaculation, decreased libido, erectile dysfunction, anorgasmia, menstrual irregularities, gynecomastia, priapism, dysuria, hyperprolactinemia, galactorrhea.

Allergic reactions: redness of the skin, urticaria; swelling of the face or lips; skin rash, generalized itching, exudative erythema multiforme.

Other: edema (including periorbital), arthralgia, lymphadenopathy, increased sweating, weight loss, withdrawal syndrome.

Interaction

Cases of serious side effects have been described in patients receiving sertraline in combination with MAO inhibitors. Concomitant use of sertraline with diazepam or tolbutamide may result in changes in serum levels of these drugs.

When taking sertraline (200 mg per day) and warfarin simultaneously, a slight increase in prothrombin time is possible. It is necessary to monitor this indicator at the beginning of treatment with sertraline and after its discontinuation. Cimetidine causes a decrease in the clearance of sertraline when used together.

Sertraline may inhibit the metabolism of tricyclic antidepressants, so caution should be exercised when using these drugs concomitantly.

Overdose

Severe symptoms from an overdose of sertraline have not been identified, even when the drug is prescribed in large doses.

Symptoms of overdose: tremor, disorientation, restlessness, muscle hypertonicity, hyperreflexia, myoclonic twitching first in the feet, then spreading throughout the body, abdominal cramps, flatulence, diarrhea, nausea, vomiting, dyspepsia.

Treatment of overdose: there are no specific antidotes. To reduce absorption, gastric lavage and the use of activated carbon are possible. It is necessary to ensure normal airway patency, oxygenation and ventilation of the lungs. The functions of vital organs should be monitored and symptomatic and supportive therapy should be provided.

Storage conditions

In a dry place, at a temperature not exceeding 25 °C

Shelf life

3 years

Manufacturer

Sun Pharmaceutical Industries Ltd, India